Analyst Upgrades

• Macquarie upgraded Intel (INTC) to outperform from neutral and Advanced Micro (AMD) to neutral from underperform.
• Pfizer (PFE) was upgraded to outperform from market perform at Bernstein.
• Capstead Mortgage (CMO) was upgraded to outperform from market perform at FBR Capital.
• Oppenheimer upgraded Halliburton (HAL) to outperform from perform.
• Gilead (GILD) was upgraded to outperform from sector perform at RBC Capital.
• Skilled Healthcare (SKH) was upgraded to outperform from market perform at JMP Securities.
• Citigroup upgraded CapitalSource (CSE) to buy from hold.

Continue reading Analyst Calls: AMD, COL, EL, GILD, HAL, INTC, PFE, SLB, SPLS ...

Analyst Calls: AMD, COL, EL, GILD, HAL, INTC, PFE, SLB, SPLS ... originally appeared on BloggingStocks on Mon, 01 Nov 2010 11:30:00 EST. Please see our terms for use of feeds.

"Gilead Sciences (GILD) is a top-rated stock on both our fundamental and technical screens; indeed, the biotech world tends to run on its own steam, and this stock seems to by capable of defying gravity;" says Mike Turner.

The editor of Trade of the Week explains, "The company, based in Foster City, California, has just about everything that I look for in a company and, by extension, its stock.

"True, the biotech sector cannot completely ignore the broader markets, but when a fundamentally and technically strong stock like this bubbles to the surface, I do not want to ignore it.

Continue reading Gilead Sciences (GILD): Defying Gravity

Gilead Sciences (GILD): Defying Gravity originally appeared on BloggingStocks on Fri, 22 Oct 2010 10:00:00 EST. Please see our terms for use of feeds.

The editor of Cabot Benjamin Graham Value Letter explains, "Gilead is a biopharmaceutical company that discovers, develops and markets therapeutic treatments to combat viral, bacterial and fungal infections. Its shares undervalued at 9.7 times forward 12-month EPS.

"Teva, based in Israel, develops, makes and sells generic and proprietary-branded (store brand) drugs. Its shares are clearly undervalued at 10.6 times forward EPS. We consider both stocks to be very low risk.

Continue reading Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA)

Ben Graham Buys in Pharma: Gilead (GILD) and Teva (TEVA) originally appeared on BloggingStocks on Thu, 14 Oct 2010 11:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Oppenheimer upgraded Teva (TEVA) to outperform from perform. The firm expects the company to generate strong 2H10 earnings and thinks the competition created by Novartis's (NVS) Gilenia will be limited.
• Citigroup upgraded Celanese (CE) to buy from hold, citing valuation and the company's move to add assets in China, as well as possible takeover interest.
• Needham raised Stereotaxis (STXS) to buy from hold as the firm thinks that strong clinical data recently announced by the company could result in faster adoption rates of its robotic surgery.
• BMO Capital upgraded Smurfit-Stone Container (SSCC) given strength in the containerboard market.
• Melco Crown (MPEL) was upgraded to buy from neutral at UBS.
• Goldman Sachs raised Temple-Inland (TIN) to buy from neutral.
• Barclays upgraded Lloyds Banking (LYG) to equal weight from underweight.

Continue reading Analyst Calls: AMGN, APOL, CE, CELG, HGSI, RIMM, STXS, SUN, TEVA, VAL ...

Analyst Calls: AMGN, APOL, CE, CELG, HGSI, RIMM, STXS, SUN, TEVA, VAL ... originally appeared on BloggingStocks on Thu, 09 Sep 2010 11:30:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Deutsche Bank upgraded Smurfit-Stone (SSCC) to buy from hold after raising its estimates for containerboard names and upped its target for shares to $28 from $22. The firm also raised its price target for International Paper (IP) to $38 from $32, for Packaging Corp. (PKG) to $33 from $28, for Temple-Inland (TIN) to $31 from $28, for Greif (GEF) to $67 from $65, and for Rock-Tenn (RKT) to $70 from $65. All stocks are buy rated.
• ThinkEquity upgraded VMware (VMW) to buy from hold and has a $90 price target on the stock. The firm expects VMware to benefit from increased virtual infrastructure adoption and improving vSphere solutions.
• Needham upgraded Cavium Networks (CAVM) to strong buy from buy, citing the recent pullback in shares following Cisco's (CSCO) cautious commentary. The firm has a $37 target on the stock.
• Intercontinental Exchange (ICE) was upgraded to outperform from neutral at Credit Suisse.
• MedAssets (MDAS) was upgraded to buy from hold at Auriga.
• Brookfield Properties (BPO) was upgraded to buy from hold at Citigroup.

Continue reading Analyst Calls: AMGN, CAVM, COCO, GENZ, GILD, ICE, PWRD, SSCC, VMW ...

Analyst Calls: AMGN, CAVM, COCO, GENZ, GILD, ICE, PWRD, SSCC, VMW ... originally appeared on BloggingStocks on Mon, 16 Aug 2010 11:30:00 EST. Please see our terms for use of feeds.

• Keefe Bruyette upgraded Goldman Sachs (GS) to Outperform from Market Perform with a $190 price target following the company's Q2 results. The firm believes the company's settlement with the SEC removes an overhang on shares.
• Stifel Nicolaus upgraded Health Care REIT (HCN) to Buy from Hold based on valuation and added shares to the Stifel REIT Income List. The firm has a $47 target on the stock.
• FBR Capital upgraded Annaly Capital (NLY) to Outperform from Market Perform citing the company's surprise dividend increase. The firm has a $20 target on the stock.
• Devon Energy (DVN) was upgraded to Overweight from Equal Weight at Barclays.
• Overseas Shipholding (OSG) was upgraded to Overweight from Underweight at JP Morgan.
• Cintas (CTAS) was upgraded to Neutral from Underperform at Baird.

Continue reading Analyst Calls: GS, HCN, NLY, YHOO, GILD, BBG, WLL, JOYG, BUCY

Analyst Calls: GS, HCN, NLY, YHOO, GILD, BBG, WLL, JOYG, BUCY originally appeared on BloggingStocks on Wed, 21 Jul 2010 11:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• Deutsche Bank upgraded Southern Copper (SCCO) to buy from hold to reflect valuation and positive near-term catalysts. The firm raised its target for shares to $38 from $35.
• JMP Securities upgraded Ultimate Software (ULTI) to outperform from market perform. The firm cites the company's expanding employee base for the upgrade. The firm has a $40 target on the stock.
• Piper Jaffray upgraded Aeropostale (ARO) to neutral from underweight following the company's Q4 results and raised its target for shares to $31 from $24.
• Kennametal (KMT) was upgraded to sell from conviction sell at Goldman.
• Lifetime Brands (LCUT) was upgraded to outperform from market perform at Barrington.
• Volvo (VOLVY) was upgraded to overweight from underweight at JPMorgan.

Continue reading Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ...

Analyst Calls: ABT, ARO, BMY, CELG, DNDN, FACT, GS, PSUN, SCCO, ULTI ... originally appeared on BloggingStocks on Fri, 12 Mar 2010 11:00:00 EST. Please see our terms for use of feeds.

Analyst Upgrades

• FBR Capital upgraded Adobe Systems (ADBE) to outperform from market perform to reflect valuation following the recent pullback in shares, as well as the upcoming release of the company's CS5 product. The firm raised its price target for the stock to $39 from $36.
• Keefe Bruyette upgraded Zenith National (ZNT) to market perform from underperform following the company's merger agreement with Fairfax Financial. The firm thinks the offer is a strong price to receive for Zenith National shareholders.
• Kaufman Bros. upgraded Infosys (INFY) to buy from hold as it believes the offshore applications outsourcing market is picking up. The firm raised its target price for shares to $67 from $58.
• Ventas (VTR) was upgraded to buy from neutral at BofA/Merrill.
• Liz Claiborne (LIZ) was upgraded to buy from hold at KeyBanc.
• iStar Financial (SFI) was upgraded to hold from sell at Citigroup.

Continue reading Analyst Upgrades, Downgrades and Initiations: ACN, ADBE, BBY, DIS, FSLR, GILD, ZNT ...

Analyst Upgrades, Downgrades and Initiations: ACN, ADBE, BBY, DIS, FSLR, GILD, ZNT ... originally appeared on BloggingStocks on Fri, 19 Feb 2010 12:00:00 EST. Please see our terms for use of feeds.

Continue reading Gilead (GILD) shelves blood pressure drug

Gilead (GILD) shelves blood pressure drug originally appeared on BloggingStocks on Tue, 15 Dec 2009 13:20:00 EST. Please see our terms for use of feeds.

From TheStreet.com Network

• Ariad Upgraded, Xenoport Drug Delayed: BioBuzz
• Holiday Deals Heat Up at Big Retailers

Continue reading Cramer on BloggingStocks: Pelosi can't kill the health care sector

Cramer on BloggingStocks: Pelosi can't kill the health care sector originally appeared on BloggingStocks on Mon, 09 Nov 2009 10:10:00 EST. Please see our terms for use of feeds.

"Gilead Sciences (NASDAQ: GILD) develops treatments for life-threatening diseases and specializes in drugs for HIV, the virus that causes AIDS," notes Hannah Choe.

The contributing editor to Personal Finance explains, "Already the market leader in HIV antivirals, Gilead is in the beginning stages of developing Quad, the first-ever, four-in-one AIDS pill.

"The manufacture of HIV drugs, which accounts for more than three-quarters of revenue, is Gilead's highest-grossing business. This segment has held up through the recession; in the second quarter product sales for the antiviral franchise grew 26% from a year ago to $1.41 billion.

Continue reading Gilead (GILD): New potential in 4-in-1 HIV drug

Gilead (GILD): New potential in 4-in-1 HIV drug originally appeared on BloggingStocks on Thu, 05 Nov 2009 13:10:00 EST. Please see our terms for use of feeds.

Last week, Goldman Sachs Group Inc. (NYSE: GS) and JPMorgan Chase & Co. (NYSE: JPM) reported stellar quarterly results. Lots more third quarter reports from the big banks are due this week.

However, analysts surveyed by Thomson Reuters anticipate year-over-year earnings declines from Bank of New York Mellon (NYSE: BK), BB&T Corp. (NYSE: BBT), M&T Bank Corp. (NYSE: MTB), Northern Trust Corp. (NASDAQ: NTRS), PNC Financial Services Group Inc. (NYSE: PNC), State Street Corp. (NYSE: STT), US Bancorp (NYSE: USB), and Wells Fargo & Co. (NYSE: WFC).

Continue reading The week in preview: High hopes for Apple, Chipotle, Travelers and more

The week in preview: High hopes for Apple, Chipotle, Travelers and more originally appeared on BloggingStocks on Sun, 18 Oct 2009 12:30:00 EST. Please see our terms for use of feeds.

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Continue reading Turnaround expert targets laggard pharmaceuticals

Turnaround expert targets laggard pharmaceuticals originally appeared on BloggingStocks on Mon, 12 Oct 2009 12:10:00 EST. Please see our terms for use of feeds.

"Gilead Sciences (NASDAQ: GILD), one of the world's largest biotechs, is a stock for all seasons," say growth expert Alexander Green.

The investment director for The Oxford Club explains, "It's a fine company with a solid balance sheet, a recession-proof business and excellent growth prospects."

"Gilead focuses on three main areas, including cardiovascular conditions and respiratory diseases. (Many may have taken its anti-influenza drug Tamiflu, Letairis to treat hypertension, or Macugen to treat macular degeneration.)

Continue reading Gilead (GILD): 'A stock for all seasons'

Gilead (GILD): 'A stock for all seasons' originally appeared on BloggingStocks on Fri, 25 Sep 2009 13:00:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Citigroup upgraded Cooper Industries (NYSE: CBE) to Buy from Hold on valuation as it believes commercial construction concerns are well known. The firm raised its target on shares to $40 from $37, and coupled the upgrade with a downgrade of Rockwell Automation (NYSE: ROK) to Sell from Hold.
• Credit Suisse upgraded BJ Services (NYSE: BJS) to Neutral from Underperform following its acquisition by Baker Hughes (NYSE: BHI). The firm raised its target to $17.
• Credit Suisse also upgraded Amkor Technology (NASDAQ: AMKR) to Outperform from Neutral and raised its target to $8 from $7. The firm expects Amkor to benefit from near-term strength in the supply chain and the mix shift towards higher value packaging.
• Textron (NYSE: TXT) was upgraded to Conviction Buy from Neutral at Goldman.
• Siemens (NYSE: SI) was upgraded to Neutral from Sell at UBS.
• Stanley Works (NYSE: SWK) was upgraded to Buy from Neutral at Janney Montgomery.

Continue reading Analyst upgrades, downgrades and initiations: ANF, BJS, CBE, GENZ, ROK, SI ...

Analyst upgrades, downgrades and initiations: ANF, BJS, CBE, GENZ, ROK, SI ... originally appeared on BloggingStocks on Wed, 02 Sep 2009 11:40:00 EST. Please see our terms for use of feeds.

The earnings crunch begins in earnest this week, and analysts surveyed by Thomson Reuters are expecting a parade of companies reporting profit declines in the just completed quarter. That includes more financials, such as American Express Co. (NYSE: AXP), Bank of New York Mellon Corp. (NYSE: BK), M&T Bank Corp. (NYSE: MTB), Northern Trust Corp. (NASDAQ: NTRS), State Street Corp. (NYSE: STT), US Bancorp (NYSE: USB), and Wells Fargo & Co. (NYSE: WFC). On the other hand, Capital One Financial Corp. (NYSE: COF), E*Trade Financial Corp. (NASDAQ: ETFC), Regions Financial Corp. (NYSE: RF), and Zions Bancorp. (NASDAQ: ZION) are expected to post losses.

This week's anticipated earnings decliners also include tech companies such as Apple Inc. (NASDAQ: AAPL), Lexmark International Inc. (NYSE: LXK), Microsoft Corp. (NASDAQ: MSFT), Qualcomm Inc. (NASDAQ: QCOM), Texas Instruments Inc. (NYSE: TXN), and Yahoo! Inc. (NASDAQ: YHOO). Advanced Micro Devices Inc. (NYSE: AMD) is expected to post a loss.

Continue reading The week in preview: Earnings crunch expected to reveal lots of lower profits

The week in preview: Earnings crunch expected to reveal lots of lower profits originally appeared on BloggingStocks on Sun, 19 Jul 2009 13:00:00 EST. Please see our terms for use of feeds.

Continue reading Gilead Sciences enters drug agreement with Tibotec Pharmaceuticals

Gilead Sciences enters drug agreement with Tibotec Pharmaceuticals originally appeared on BloggingStocks on Fri, 17 Jul 2009 12:20:00 EST. Please see our terms for use of feeds.

Few would argue with the claim that Gilead Sciences (NASDAQ: GILD) is the best-managed biopharma company on the planet.

It dominates the HIV treatment market and gets a 19%-plus royalty on Tamiflu, which is used to treat H1N1 (swine) flue. Gilead also has several drugs on or headed for the market to treat pulmonary disease and hard-to-treat high blood pressure.

Your best strategy for life-changing profits?

Buy the stock and sell the calls (then use the cash to buy puts on the market, which is headed down further.) Or buy long-term calls and keep an eye on them.

Next: Biotech Stock #2

Biotech stock #1: Gilead Sciences (GILD) originally appeared on BloggingStocks on Sat, 11 Jul 2009 09:00:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• UBS upgraded Target (NYSE: TGT) to Buy from Neutral and raised its price target to $52 from $45 citing reduced inventories, some credit stability, and an improved back-to-school period.
• Credit Suisse said concerns regarding Safeway's (NYSE: SWY) price position are overblown and that earnings risk is limited. The firm upgraded shares to Outperform from Neutral and raised the target price to $25 from $22.
• Oppenheimer upgraded Canadian Solar (NASDAQ: CSIQ) to Outperform from Perform as it believes the story is underappreciated following the recent sector rally. The firm has a $14 price target on the stock.
• CME Group (NASDAQ: CME) was upgraded to buy from Neutral at Goldman.
• Freeport McMoRan (NYSE: FCX) was upgraded to Overweight from Neutral at JP Morgan.
• Gilead Sciences (NASDAQ: GILD) was upgraded to Buy from Neutral at FTN Equity.

Continue reading Analyst upgrades, downgrades and initiations: TGT, SWY, CSIQ, HOTT, MPEL, RIO, CPB, CVD and HGG

Analyst upgrades, downgrades and initiations: TGT, SWY, CSIQ, HOTT, MPEL, RIO, CPB, CVD and HGG originally appeared on BloggingStocks on Thu, 21 May 2009 11:10:00 EST. Please see our terms for use of feeds.

Analyst upgrades:

• Citigroup upgraded Lennar (NYSE: LEN) to Buy from Hold as it believes the company's near-term liquidity profile is improved following the $400M debt issuance. The firm raised its target price to $12 from $11.
• Jefferies upgraded Rowan Companies (NYSE: RDC) to Buy from Hold as it believes jack-up drillers will continue to outperform deepwater names. The firm raised its target price to $27 from $20.
• Keefe Bruyette upgraded First Financial (NASDAQ: FFIN) to Market Perform from Underperform to reflect more positive loan data for the Texas banks. The firm raised its target price on shares to $44 from $38.
• MGM Mirage (NYSE: MGM) was upgraded to Overweight from Neutral at JP Morgan.
• Morgan Stanley (NYSE: MS) was upgraded to Outperform from Market Perform at JMP Securities.
• Brinker (NYSE: EAT) was upgraded to Overweight from Equal Weight at Barclays.

Continue reading Analyst upgrades, downgrades and initiations: LEN, RDC, FFIN, SII, AN, ACHN, UA, LULU, JST

Analyst upgrades, downgrades and initiations: LEN, RDC, FFIN, SII, AN, ACHN, UA, LULU, JST originally appeared on BloggingStocks on Mon, 18 May 2009 10:30:00 EST. Please see our terms for use of feeds.